Stock Forecast Chart
Stock Price Prediction Summary
Forecast Score Based on 2 Weeks
Based on our forecast, the price of RNAZ will decline by -48.47% over the next 2 Weeks and hit $0.87 by Friday, September 25, 2026. In that time frame, RNAZ's share price is expected to range between $0.67 and $1.06.
BearishAverageBullish| Date | Predicted Lower | Predicted | Predicted Upper |
|---|---|---|---|
| Sep 25, 2026 | 0.67 | 0.87 | 1.06 |
| Sep 24, 2026 | 0.82 | 1.01 | 1.22 |
| Sep 23, 2026 | 0.77 | 0.97 | 1.17 |
| Sep 22, 2026 | 0.86 | 1.04 | 1.22 |
| Sep 21, 2026 | 0.93 | 1.11 | 1.30 |
| Sep 18, 2026 | 1.07 | 1.24 | 1.42 |
| Sep 17, 2026 | 1.21 | 1.39 | 1.57 |
| Sep 16, 2026 | 1.16 | 1.34 | 1.52 |
| Sep 15, 2026 | 1.23 | 1.41 | 1.59 |
| Sep 14, 2026 | 1.31 | 1.49 | 1.68 |
RNAZ shares remained flat 0 in Friday, September 11, 2026's trading session, starting and closing at a previous close of $1.69 to move at $1.69. The stock demonstrated notable intraday movement (see RNAZ's key stats for a full breakdown), fluctuating between $1.63 and $1.73, a +6.36% trading range. While recent weeks have seen some volatility, RNAZ has managed to secure a -22.48% drop over the past 2 weeks. The neutral price movement was accompanied by decreased trading volume, with approximately 11.44K shares changing hands, 14.09K fewer than the previous session. This amounted to $19.34K in total market activity.
Will RNAZ Continue Its Downward Trend?
According to analyst ratings and projections for RNAZ, TransCode Therapeutics, Inc. shares are anticipated to decrease by -58.69%, potentially reaching $1.06 per share by September 25, 2026. Short-term technical indicators for RNAZ currently suggest a bearish sentiment. This aligns with the stock's recent performance, as it has recorded 25 negative trading days within the past 30 sessions. Based on the RNAZ stock forecast, now is not the best time to buy RNAZ stock because its current trading price is +94.05% above our predicted value, hinting at a possible undervaluation. For deeper insights, view our sentiment analysis on RNAZ covering social and institutional perspectives.
RNAZ Technical Momentum: Overbought, Oversold, or Neutral?
An analysis of Relative Strength Index (RSI) indicators provides insight into RNAZ's momentum. Short-term RSIs (9, 14, and 20-day figures ranging from 14.18% to 26.20%) suggest the stock is in a strong bearish momentum phase. The 50-day RSI, at 37.00%, hints at potential weakness developing in the medium term. Additionally, the 100-day RSI, at 40.59%, maintains a neutral outlook for the long term. Insights into RNAZ's shareholder base show how institutional investors are positioning themselves during these momentum shifts
TransCode Therapeutics Short-Term Forecasts
RNAZ Forecast For Next 5 Days
Our algorithm anticipates TransCode Therapeutics (RNAZ) stock could hit $1.68 by Sep 18, 2026. This represents a -0.49% rise from today's price, following a +9.94% change over the past five days.
RNAZ Forecast For Next 30 Days
Based on analysis of market trends, the outlook for TransCode Therapeutics, Inc. (RNAZ) stock over the next 30 days is largely negative. Price forecasts suggest an average target of $0.91, which would mean a -46.15% decrease from the current price of $1.69. Projections for this period range from a high of $3.07 to a low of $0.00.
RNAZ Forecast For Next 90 Days
Our proprietary market analysis suggests predictions for TransCode Therapeutics's price over the next three months point to a drop. RNAZ stock is expected to peak at $356.37 on Nov 03, 2026 before potentially dipping to $0.00 on Dec 11, 2026. On average, RNAZ is likely to trade around $0.00 in the coming 90 days.
TransCode Therapeutics Stock Forecast 2025
Based on our predictive models, TransCode Therapeutics (RNAZ) is expected to trade between $0.00 and $356.37 throughout 2026. This would result in an average price of $0.00, potentially offering investors a -100.00% return from current levels.
TransCode Therapeutics, Inc. Monthly Forecast 2026–2027
September 2026
According to our latest forecast models, TransCode Therapeutics, Inc. (RNAZ) is positioned to show a strong performance in September 2026. The price is predicted to move between $0.00 and $337.41, settling at an average of $0.00. This could translate to a -100.00% loss.
October 2026
Based on current market signals, TransCode Therapeutics, Inc. is projected to trend october 2026. We forecast a trading range from $0.00 to $310.76, with a likely average price of $0.00. Investors could expect a potential return of -100.00%.
November 2026
Our predictive algorithms indicate TransCode Therapeutics, Inc. stock may see a shift in November 2026. The expected range spans $0.00–$356.37, with an average target of $0.00. This represents a cautious outlook and a possible loss of -100.00%.
December 2026
Analyzing established trends, TransCode Therapeutics, Inc. looks set to move in December 2026. Projections place the stock between $0.00 and $316.10, averaging around $0.00. This suggests a -100.00% loss from current levels.
January 2027
Market indicators suggest TransCode Therapeutics, Inc. could experience notable changes during January 2027. Prices could fluctuate within $0.00 to $317.27, with a midpoint forecast of $0.00. The stock might deliver a -100.00% loss.
February 2027
Forecasting for February 2027, models estimate that TransCode Therapeutics, Inc. may undergo key fluctuations. If trends hold, the stock might trade between $0.00 and $347.44, averaging $0.00. This signals a cautious trajectory with potential returns around -100.00%.
March 2027
According to our latest forecast models, TransCode Therapeutics, Inc. (RNAZ) is positioned to show a strong performance in March 2027. The price is predicted to move between $0.00 and $347.63, settling at an average of $0.00. This could translate to a -100.00% loss.
April 2027
Based on current market signals, TransCode Therapeutics, Inc. is projected to trend april 2027. We forecast a trading range from $0.00 to $348.68, with a likely average price of $0.00. Investors could expect a potential return of -100.00%.
May 2027
Our predictive algorithms indicate TransCode Therapeutics, Inc. stock may see a shift in May 2027. The expected range spans $0.00–$353.88, with an average target of $0.00. This represents a cautious outlook and a possible loss of -100.00%.
June 2027
Analyzing established trends, TransCode Therapeutics, Inc. looks set to move in June 2027. Projections place the stock between $0.00 and $366.63, averaging around $0.00. This suggests a -100.00% loss from current levels.
July 2027
Market indicators suggest TransCode Therapeutics, Inc. could experience notable changes during July 2027. Prices could fluctuate within $0.00 to $340.70, with a midpoint forecast of $0.00. The stock might deliver a -100.00% loss.
August 2027
Forecasting for August 2027, models estimate that TransCode Therapeutics, Inc. may undergo key fluctuations. If trends hold, the stock might trade between $0.00 and $355.65, averaging $0.00. This signals a cautious trajectory with potential returns around -100.00%.
September 2027
According to our latest forecast models, TransCode Therapeutics, Inc. (RNAZ) is positioned to show a strong performance in September 2027. The price is predicted to move between $0.00 and $310.62, settling at an average of $0.00. This could translate to a -100.00% loss.
RNAZ's history of dividends and stock splits also plays a role in long-term investor confidence.